Company Overview of Regen BioPharma Inc.
Regen BioPharma Inc. develops medicine platforms for the rapid commercialization of stem cell therapies. The company was founded in 2012 and is based in the United States. Regen BioPharma Inc. operates as a subsidiary of Bio-Matrix Scientific Group, Inc.
4700 Spring Street
La Mesa, CA 91942
Founded in 2012
Key Executives for Regen BioPharma Inc.
Chief Scientific Officer
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.
Regen BioPharma Inc. Key Developments
Regen BioPharma Inc. Presents Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at American Society of Hematology Annual Meeting
Dec 11 14
Regen BioPharma Inc. announced that it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. The company recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6. The work entitled NR2F6 (EAR-2) is a novel leukemia oncogene whose cellular function is to regulate terminal differentiation of Erythrocytes at the Proerythroblast Stage was presented as abstract #1337 at the Moscone Center in San Francisco on Saturday, December 6, 2014 by Dr. Christine Ichim, Senior Research Consultant to the company.
Regen BioPharma, Inc. Issues Investigational New Drug Application Number 16200 from the FDA
Nov 4 14
Regen BioPharma Inc. announced issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer. The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months. Regen's dCellVax therapy is based on US Patent # 8,389,708, acquired from Professor Wei-Ping Min at the University of Western Ontario, Canada, as well as a collaboration between Dr. Min and the Company's Chief Science Officer Dr. Thomas Ichim. Preclinical studies have demonstrated efficacy in mouse models of breast cancer and melanoma.
Regen Biopharma Inc. Appoints Amit Patel to its Scientific Advisory Board
Oct 15 14
Regen BioPharma Inc. announced the appointment of Dr. Amit Patel to the company's Scientific Advisory Board (SAB). Dr. Patel is Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah and has been involved in over 17 FDA trials in the area of cellular therapy.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries